Peter M Levine

US Patent:

6387366, May 14, 2002

Filed:

Dec 31, 1998

Appl. No.:

09/224048

Inventors:

David R. Hurwitz - Boston MA
Van Cherington - Harvard MA
Theofanis Galanopoulos - Arlington MA
Peter H. Levine - Worcester MA
Joel S. Greenberger - Sewickley PA

Assignee:

ALG Company - Marlboro MA

International Classification:

A01N 6300

US Classification:

424 931, 424 932, 4241301, 424 9321, 514 44, 435325

Abstract:

The methods of the present invention are based on the discovery that adverse side effects (such as hemorrhage) can occur upon infusion of cells that express tissue factor. Accordingly, the methods of the invention are aimed at reducing the biological activity of tissue factor (TF) in a patient, and can be carried out by, for example: infusing fewer cells (or infuse the same number of BMSCs over a longer period of time); reducing the expression or activity of TF (within the infused cells specifically (e. g. , by contacting the cells with a TF antagonist in vitro) or within the patient generally (e. g. , by administering a TF antagonist to the patient); hampering the interaction of TF with factor VII(a); inhibiting the activity of the TF-factor VII(a) complex once it has formed; or inhibiting the coagulation cascade at any point downstream from formation of the complex (including inhibition of platelet activation).

US Patent:

58492879, Dec 15, 1998

Filed:

Mar 22, 1995

Appl. No.:

8/408536

Inventors:

Joel S. Greenberger - Lincoln MA
Peter H. Levine - Worcester MA

Assignee:

Stromagene Corporation - Lincoln MA
Gene Therapy Sciences, Inc. - Worcester MA

International Classification:

A61K 4800
C12N 510

US Classification:

424 9321

Abstract:

A method of causing production and secretion into the bloodsream of a human patient of a biologically active enzyme for which the human patient suffers a deficiency; the method involves introducing into the human patient donor bone marrow stromal cells which have been transfected with a gene encoding the enzyme, so that the introduced cells can adhere to a bone cavity surface of the patient and produce and secrete the active enzyme.

US Patent:

59938013, Nov 30, 1999

Filed:

Aug 19, 1997

Appl. No.:

8/914631

Inventors:

Joel S. Greenberger - Lincoln MA
Peter H. Levine - Worcester MA

Assignee:

ALG Company - Marlboro MA

International Classification:

A01N 6300

US Classification:

424 9321

Abstract:

A method of causing production and secretion into the bloodstream of a human patient of a biologically active enzyme for which the human patient suffers a deficiency; the method involves introducing into the human patient donor bone marrow stromal cells which have been transfected with a gene encoding the enzyme, so that the introduced cells can adhere to a bone cavity surface of the patient and produce and secrete the active enzyme.